Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author does not hold a position in TWST.

← Back to Free Index

TWST

Analysis as of: 2026-08-28

Twist Bioscience Corporation

Twist Bioscience manufactures synthetic DNA products, genomics workflow tools, and antibody discovery inputs used by biotech, pharma, diagnostics, industrial, government, and academic customers.

ai automation biotech healthcare

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

AI biology volume meets scarce trusted execution

The debate is not whether AI will create more biological designs; it is whether the scarce step of building them can hold premium economics. Recent execution and new capital make a roughly 2x five-year equity outcome plausible, but only if volume converts into durable cash generation.

Analysis

Thesis

Twist is a rare AI-biology picks-and-shovels company where cheaper design should increase demand for its physical output; if it converts that demand into higher utilization, strategic supply agreements, and trusted workflow revenue, revenue can scale sharply by 2031 even as the valuation multiple normalizes.

Last Economy Alignment

AI should increase the number of biological designs that need to be built and tested, and Twist controls a real manufacturing-and-trust layer. The risk is not demand creation but whether DNA supply stays differentiated enough to hold pricing and margin.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

1.7x (from 5 most recent analyses)

Reasoning

The opportunity is large enough for operating growth to outrun valuation compression. Twist already has real demand, improving margins, and fresh capital to add capacity; if it deepens into higher-trust workflows instead of staying a catalog supplier, shareholders can still see roughly a doubling over five years.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The main risk is value capture, not end demand. AI can expand biology design volume, but Twist still must prove that added capacity, better mix, and trust-based positioning translate into durable pricing power, cash generation, and less dilution, while also reducing a meaningful supplier bottleneck.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

Anthropic disclosed on August 18, 2026 that Twist was selected as an independent evaluator for an AI-designed protein campaign, adding credibility to the AI-biologics angle.
No follow-on commercial terms or recurring program details were disclosed, so the new AI signal improves option value more than near-term revenue visibility.
There was no new disclosure in the last 7-10 days on qualifying a second source for the critical synthesis input, so the key operational bottleneck remains unchanged.

Thesis update

The core thesis is intact, but recent evidence modestly improves confidence that Twist can participate directly in AI-enabled biology workflows rather than only benefit indirectly.

Forecast update

Fresh capital lowered near-term financing fragility and widened the funded path to absorb demand, which modestly improves equity upside despite dilution.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.48

They own a real factory and ordering layer that turns AI-generated biology designs into physical products, so more AI design work can send more volume their way. The risk is that if DNA ordering stays mostly about price and speed, they become busier without keeping much of the extra value.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$105.30

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research